We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYTH
151
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-947,900
Closed -$47.5M
CTRX
152
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-120,000
Closed -$7.14M
ACT.PRA
153
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
– –
-104,200
Closed -$105M
ASPX
154
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-118,600
Closed -$11.9M
SLXP
155
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-82,000
Closed -$14.2M
UPI
156
DELISTED
UROPLASTY INC-NEW
UPI
– –
-1,363,500
Closed -$1.66M
DSCI
157
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-300,000
Closed -$2.54M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.